Biotechnology R&D contract awarded to PPD Development LP for over $27M, spanning 11 years

Contract Overview

Contract Amount: $27,247,204 ($27.2M)

Contractor: PPD Development LP

Awarding Agency: Department of Health and Human Services

Start Date: 2011-12-16

End Date: 2023-02-22

Contract Duration: 4,086 days

Daily Burn Rate: $6.7K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 7

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: TAS::75 0885::TAS NIAID DAIT CLINICAL SITE MONITORING CENTER

Place of Performance

Location: WILMINGTON, NEW HANOVER County, NORTH CAROLINA, 28401

State: North Carolina Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $27.2 million to PPD DEVELOPMENT LP for work described as: TAS::75 0885::TAS NIAID DAIT CLINICAL SITE MONITORING CENTER Key points: 1. Contract value appears reasonable given the extensive 11-year duration and the nature of R&D services. 2. Full and open competition suggests a healthy market for these specialized services. 3. Long contract duration may present risks related to evolving research needs and technological obsolescence. 4. Performance context is within clinical site monitoring for research, a critical but complex area. 5. Sector positioning is in R&D, specifically biotechnology, a high-growth and high-investment field. 6. The contract type (Cost Plus Fixed Fee) is common for R&D where scope can evolve.

Value Assessment

Rating: good

The contract's total value of over $27 million spread across 11 years suggests an average annual spend of approximately $2.47 million. This appears to be a fair valuation for long-term, specialized clinical site monitoring services in the biotechnology sector. Benchmarking against similar long-term R&D support contracts would provide further insight, but the duration and scope indicate a significant investment.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple qualified bidders had the opportunity to submit proposals. The presence of 7 bidders suggests a competitive marketplace for these services. This level of competition is generally favorable for price discovery and ensuring the government receives competitive offers.

Taxpayer Impact: Full and open competition typically leads to better pricing for taxpayers by fostering a competitive environment among potential contractors.

Public Impact

The primary beneficiaries are researchers and institutions involved in biotechnology R&D, who receive essential support services. Services delivered include clinical site monitoring, crucial for ensuring the integrity and validity of research data. The geographic impact is primarily in North Carolina, where the contractor is located, but the research supported may have broader national or global implications. Workforce implications include the employment of skilled professionals in clinical research, monitoring, and project management within the biotechnology sector.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Long contract duration (11 years) increases the risk of cost overruns if research needs or technologies change significantly.
Cost Plus Fixed Fee contracts can incentivize contractors to incur more costs if the fixed fee is substantial relative to the effort.
Reliance on a single contractor for an extended period could lead to vendor lock-in and reduced flexibility.

Positive Signals

Full and open competition with 7 bidders suggests a robust market and potential for competitive pricing.
The contract's long-term nature indicates a sustained need for these specialized R&D support services.
The contractor's involvement over an extended period may lead to deep institutional knowledge and efficient service delivery.

Sector Analysis

This contract falls within the Research and Development (R&D) sector, specifically focusing on Biotechnology (NAICS 541711). The biotechnology R&D market is characterized by significant investment, long development cycles, and a need for specialized expertise in areas like clinical trial management. Comparable spending benchmarks would involve looking at other government contracts supporting NIH-funded research or similar large-scale R&D initiatives.

Small Business Impact

The data indicates this contract was not set aside for small businesses (ss: false, sb: false). Given the specialized nature and long duration of the contract, it is likely that larger, established firms with extensive experience in clinical site monitoring and R&D support were best positioned to compete. There is no explicit information on subcontracting plans, but large contracts often involve opportunities for small businesses to participate as subcontractors.

Oversight & Accountability

Oversight for this contract would primarily fall under the National Institutes of Health (NIH), a component of the Department of Health and Human Services. Mechanisms likely include regular performance reviews, financial audits, and adherence to contractual milestones. Transparency is generally maintained through contract databases, though specific project details may be proprietary. Inspector General jurisdiction would apply to any allegations of fraud, waste, or abuse.

Related Government Programs

NIH Research Grants
Biotechnology Research and Development Support
Clinical Trial Management Services
Federal R&D Contracting
Health and Human Services Contracts

Risk Flags

Long contract duration may lead to scope creep or obsolescence.
Cost Plus Fixed Fee structure requires careful monitoring to control costs.
Potential for vendor lock-in due to extended contract period.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $27.2 million to PPD DEVELOPMENT LP. TAS::75 0885::TAS NIAID DAIT CLINICAL SITE MONITORING CENTER

Who is the contractor on this award?

The obligated recipient is PPD DEVELOPMENT LP.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $27.2 million.

What is the period of performance?

Start: 2011-12-16. End: 2023-02-22.

What is the track record of PPD Development LP with federal contracts, particularly with NIH?

PPD Development LP has a significant history of federal contracting, particularly with agencies like the Department of Health and Human Services (HHS) and its components such as the National Institutes of Health (NIH). Their involvement often centers around providing research and development services, including clinical trial support, site monitoring, and data management. Analyzing their past performance on similar contracts, including any reported issues or successes, would provide a clearer picture of their reliability and capability in fulfilling the requirements of this specific contract. A review of contract databases and performance reports would be necessary to fully assess their track record.

How does the value of this contract compare to similar long-term R&D support contracts awarded by NIH?

The total contract value of over $27 million spread across 11 years equates to an average annual expenditure of approximately $2.47 million. To benchmark this effectively, one would need to compare it against other definitive contracts awarded by NIH or similar agencies for comparable services, such as clinical site monitoring, data analysis, and project management within the biotechnology R&D sphere. Factors like the specific scope of work, the complexity of the research supported, and the prevailing market rates for such specialized services at the time of award are crucial for a meaningful comparison. Without direct comparative data on similar long-term R&D support contracts, it's challenging to definitively state if this represents a premium or a discount.

What are the primary risks associated with a Cost Plus Fixed Fee (CPFF) contract of this duration?

Cost Plus Fixed Fee (CPFF) contracts, especially those spanning over a decade, carry inherent risks. For the government, the primary risk is that the contractor may have less incentive to control costs compared to fixed-price contracts, as their profit is a fixed amount regardless of the actual costs incurred (within allowable limits). This can lead to cost overruns if not managed diligently. For the contractor, there's a risk if the fixed fee is underestimated relative to the effort required, or if unforeseen complexities arise that significantly increase costs beyond what was anticipated. The long duration amplifies these risks, as the research landscape, technologies, and regulatory requirements can change substantially over 11 years, potentially making the original scope and fee less relevant or adequate.

How effective is full and open competition in ensuring value for money for R&D services like clinical site monitoring?

Full and open competition is generally considered the most effective method for ensuring value for money, as it allows the widest possible pool of qualified contractors to bid, thereby fostering a competitive environment. For specialized R&D services like clinical site monitoring, this means that multiple firms can present their capabilities and pricing, allowing the government to select the offer that provides the best combination of technical merit and cost. The fact that 7 bidders participated in this contract suggests a healthy level of competition, which typically drives down prices and encourages innovation. However, the effectiveness also depends on the clarity of the solicitation, the evaluation criteria, and the government's ability to accurately assess technical proposals alongside cost.

What are the implications of the contract's location in North Carolina for federal R&D spending distribution?

The contract's designation of North Carolina (NC) as the place of performance indicates a concentration of federal R&D spending in that state, specifically within the biotechnology sector. North Carolina has a well-established life sciences cluster, often supported by state and local initiatives, which likely made it an attractive location for PPD Development LP and potentially other bidders. This spending contributes to the local economy through job creation, infrastructure utilization, and support for ancillary businesses. While this specific contract benefits North Carolina, federal R&D spending is distributed across the nation based on research strengths, institutional capabilities, and strategic priorities of agencies like the NIH.

How does the 'Research and Development in Biotechnology' classification (NAICS 541711) position this contract within the broader federal R&D landscape?

The NAICS code 541711, 'Research and Development in Biotechnology,' places this contract squarely within a critical and rapidly evolving segment of the federal R&D portfolio. This sector is vital for advancing medical treatments, agricultural innovations, and industrial processes. Federal investment in biotechnology R&D is substantial, driven by agencies like NIH, NSF, and DoD, aiming to foster scientific discovery and translate it into practical applications. Contracts under this classification often involve long-term projects, significant intellectual property considerations, and a high degree of scientific and technical complexity, requiring specialized expertise that PPD Development LP appears to possess.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Offers Received: 7

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 929 N FRONT ST, WILMINGTON, NC, 28401

Business Categories: Category Business, Not Designated a Small Business, Partnership or Limited Liability Partnership, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $66,339,563

Exercised Options: $27,247,204

Current Obligation: $27,247,204

Actual Outlays: $3,442,224

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline